Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1067807 | 1.00 | SPHK1 (0.50) | SPHK1NR1H2HSD11B2BRD4CHRM2 | |
| SCHEMBL1526136 | 1.00 | SPHK1 (0.50) | SPHK1NR1H2HSD11B2BRD4CHRM2 | |
| SCHEMBL15318844 | 0.88 | SPHK1 (0.48) | SPHK1NR1H2HSD11B2BRD4CHRM2 | |
| SCHEMBL1068506 | 0.88 | SPHK1 (0.48) | SPHK1NR1H2HSD11B2BRD4CHRM2 | |
| SCHEMBL30695331 | 0.88 | SPHK1 (0.51) | SPHK1NR1H2HSD11B2BRD4CHRM2 | |
| SCHEMBL1068504 | 0.88 | SPHK1 (0.48) | SPHK1NR1H2HSD11B2BRD4CHRM2 | |
| SCHEMBL20621505 | 0.88 | SPHK1 (0.53) | SPHK1NR1H2HSD11B2BRD4CHRM2 | |
| SCHEMBL6125269 | 0.88 | SPHK1 (0.53) | SPHK1NR1H2HSD11B2BRD4CHRM2 | |
| SCHEMBL26468958 | 0.88 | SPHK1 (0.53) | SPHK1NR1H2HSD11B2BRD4CHRM2 | |
| SCHEMBL13110172 | 0.87 | SPHK1 (0.49) | SPHK1NR1H2HSD11B2BRD4CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137083-A1 | HETEROCYCLYL PYRIDAZINE AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2026-05-21 | — | — | US | disclosed |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12501900-B2 | Heterocyclyl pyridazine as fungicidal compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| CN-119968362-A | Indazole derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2025-05-09 | — | — | CN | disclosed |
| EP-4499624-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-02-05 | — | — | EP | disclosed |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-4371982-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-3583096-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20240016152-A1 | ACTIVE COMPOUND COMBINATIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-18 | — | — | US | disclosed |
| EP-1740522-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D SB 3 /SB RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006034093-A2 | 3- (2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ELLI LILLY AND COMPANY (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060025474-A1 | Bisphenyl compounds useful as vitamin D3 receptor agonists | CHUGAI SEIYAKU KABUSHIKA KAISHA (JP) | 2006-02-02 | — | — | US | disclosed |
| US-20050222422-A1 | Compounds active in spinigosine 1-phosphate signaling | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2005-10-06 | — | — | US | disclosed |
| WO-2005087700-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D3 RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-09-22 | — | — | WO | disclosed |
| EP-1546110-A2 | COMPOUNDS ACTIVE IN SPHINGOSINE 1-PHOSPHATE SIGNALING | University of Virginia Patent Foundation (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005041899-A2 | ORALLY AVAILABLE SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS AND ANTAGONISTS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2004010949-A2 | COMPOUNDS ACTIVE IN SPINIGOSINE 1-PHOSPHATE SIGNALING | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2004-02-05 | — | — | WO | disclosed |
| US-5578627-A | FOR TREATING CEREBRAL CIRCULATORY DISORDER, HEAD INJURY SEQUELAE AND/OR EPILEPSY | TOYAMA CHEMICAL CO., LTD. (JP) | 1996-11-26 | — | — | US | disclosed |
| EP-0665226-A1 | NOVEL 1,2-BENZISOXAZOLE DERIVATIVE OR SALT THEREOF, AND BRAIN PROTECTIVE AGENT COMPRISING THE SAME | TOYAMA CHEMICAL CO., LTD. (JP) | 1995-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | SPHK1 1446/4885NR1H2 3543/4885HSD11B2 3719/4885 |
| US-20240016152-A1 | ACTIVE COMPOUND COMBINATIONS | CYP51A1, ERG28, BROX | SPHK1 2745/4885NR1H2 3598/4885HSD11B2 139/4885 |
| US-20050222422-A1 | Compounds active in spinigosine 1-phosphate signaling | S1PR1, S1PR3, S1PR5 | SPHK1 6/4885NR1H2 363/4885HSD11B2 1189/4885 |
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM2, TRPV1 | SPHK1 1088/4885NR1H2 775/4885HSD11B2 1986/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | SPHK1 4476/4885NR1H2 95/4885HSD11B2 1259/4885 |
| US-20060025474-A1 | Bisphenyl compounds useful as vitamin D3 receptor agonists | VDR, CYP2R1, CYP24A1 | SPHK1 2158/4885NR1H2 45/4885HSD11B2 677/4885 |
| US-12501900-B2 | Heterocyclyl pyridazine as fungicidal compounds | PNPO, PDXK, BLVRB | SPHK1 1260/4885NR1H2 4321/4885HSD11B2 2130/4885 |
| US-20260137083-A1 | HETEROCYCLYL PYRIDAZINE AS FUNGICIDAL COMPOUNDS | CBR1, CBR3, CYC1 | SPHK1 978/4885NR1H2 1734/4885HSD11B2 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.